Although the use of non-myeloablative stem cell transplantation (NST) reduces the severity of graft-versus-host disease (GVHD), GVHD remains a major complication following allogeneic transplantation. Since following NST in comparison with myeloablative conditioning, higher proportions of host immunohematopoietic cells may persist while donor-derived alloreactive lymphocytes are being infused, thus possibly serving as host antigen presentation for continuous stimulation of donor T cells, we speculated that GVHD may be similarly amplified by conditioning followed by intentional administration of host cells. This hypothesis was tested in a preclinical animal model. Increased incidence of GVHD, higher mortality and increased levels of chimerism were observed in recipients reconstituted with host cells, particularly with non-irradiated spleen cells. Graft-versus-leukemia effect was not impaired by post transplant cell administration. These results suggest that GVHD may be amplified by recipient cell infusion using either irradiated or viable stimulatory host cells, thus possibly explaining in part higher than anticipated incidence of GVHD and rapid displacement of host cells and conversion to 100% donor type cells following NST. Administration of irradiated host antigen-presenting cells post transplantation may thus represent a potential approach for amplification of the alloreactive capacity of donor lymphocytes following stem cell transplantation.
Introduction
The aim of allogeneic non-myeloblative stem cell transplantation (NST) is to induce graft-versus-host reaction by alloreactive donor lymphocytes following induction of hostversus-graft tolerance mediated by fast and durable engraftment of donor stem cells. Successful NST can be accomplished by well-tolerated and safer procedure, focusing on lymphoablative rather than myeloablative conditioning, aiming for immune elimination of all hematopoietic cells of host origin, all malignant cells included, not excluding tumor cells resistant to high-dose myeloablative chemoradiotherapy. [1] [2] [3] As mixed chimerism resulting from persistence of host in parallel with donor stem cells was shown to be associated with reduced incidence of graft-versus-host disease (GVHD) in experimental animals and man, [4] [5] [6] it was anticipated that NST will also result in reduced incidence of severe GVHD. Clinical application of NST has already reduced transplant-related toxicity, mortality and GVHD; 7 nevertheless, a more substantial reduction was expected and GVHD remains a major problem yet to be overcome. 1, 2 As a consequence of reducedintensity conditioning, it seems reasonable that higher proportions of host cells serving as antigen presentation remain in the recipient following the conditioning, ready to stimulate alloreactive donor lymphocytes shortly after infusion. Thus, one possible explanation for higher than anticipated incidence of GVHD following NST could be owing to stimulatory remaining in the host, until all such cells are eliminated by the GVHD process induced by donor cells. [8] [9] [10] [11] In order to evaluate the possible effect of persistence of residual host cells on GVHD and graft-versus-leukemia (GVL), the following experiments were carried out in a preclinical experimental model in mice, using parental to F1 hybrid allografting for induction of GVHD and GVL effects against B-cell leukemia/lymphoma (BCL1) of BALB/c origin. 12 
Materials and methods

Animals
Two to 4 months old inbred male and female C57BL/6 (B6) and (BALB/c Â C57BL/6)F 1 (F 1 ) used as donors and recipients, respectively, were purchased from Harlan Breeding Facility (Jerusalem, Israel). Mice were kept under clean (SPF) conditions with autoclaved cages and sawdust. Food and acidified water were supplied ad libitun.
Total body irradiation Recipient mice were placed in radiation chambers on day À1 and exposed to a submyeloablative dose of total body irradiation (TBI) 700 cGy (900 cGy is lethal if no additional spleen or marrow stem cells are administered; data not shown) delivered by a linear accelerator (Varian Clinac 6X) at a dose rate of 179 cGy/min, at a source-to-skin distance of 80 cm.
Preparation of spleen cells for induction of GVHD and for recipient cell infusion Spleens were removed aseptically from B6 mice, teased through a nylon mesh into RPMI 1640 medium (Life Technologies, Grand Island, NY, USA) to create a singlecell suspension that was injected into the lateral tail vein of each recipient. Irradiated cells were exposed to a dose of 1000 cGy to prevent possible cell replication.
Preparation of peritoneal exudates
Peritoneal exudate (PE) cells were prepared by intraperitoneal (i.p.) injection of 2 cm 3 thioglycolate into F1 mice (other than those later used for the transplants) 4 days before collection of PE. On collection day, 8-10 ml of NaCl 0.9% with heparin were injected i.p. and ascites fluid was collected. Cells contained in the PE were centrifuged and counted.
Murine B-cell leukemia BCL1 was maintained in vivo in BALB/c mice by intravenous passage of 10 6 -10 7 peripheral blood lymphocytes (PBLs) obtained from tumor-bearing mice. 12 It was previously shown that even a small inoculum of BCL1 might be sufficient to cause typical leukemia in all recipients. 12, 13 All recipients of 410-100 BCL1 develop splenomegaly and marked lymphocytosis in the blood. PBL counts of all experimental animals were carried out weekly. Assay for the presence of BCL1 was also analyzed by PCR at 7 days after transplantation to assess persistence of residual leukemia cells in the spleen, as described previously. 14 Adoptive transfer experiments to determine efficacy of RCI on GVL effects against BCL1 Untreated BALB/c mice receiving 10 5 spleen cells obtained from each experimental group were used to determine by adoptive transfer whether or not clonogenic BCL1 were still present in the spleen of treated mice. Recipients were observed for the development of leukemia for at least 150 days. Splenomegaly and PBL counts were monitored to confirm the presence of leukemia and to determine if leukemia was indeed the cause of death.
PCR for BCL1
PCR for BCL1 was carried out as described previously. 14 Briefly, genomic DNA was isolated from 300 ml of fresh whole blood with the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA). DNA (0.2 mg/sample) was amplified in a 50 ml reaction buffer containing 1 Â PCR buffer, 2.25 mM MgCl 2 , 0.1 mg/ml bovine serum albumin, 0.2 mM deoxynucleoside triphosphates, 20 pmol of each primer, using primers with the following sequence: 5
0 of the murine BCL1 rearranged Vh region. Samples were vortexed, boiled 5 min and chilled on ice before adding 1 U taq polymerase (MBI, Fermentas, UAB, Vilnius, Lithuania). Thirty-five amplification cycles were preformed, each cycle consisting of a denaturation step at 941C for 1 min, annealing step at 501C for 1.5 min and an extension step at 721C for 2 min. Following these 35 cycles, an additional extension was preformed at 721C for 7 min. PCR products were separated on an 18% agarose gel and stained with ethidium bromide to assess their size.
Assay for cytokines
The levels of tumor necrosis factor (TNF)a and g-interferon in the plasma of treated mice were determined by 'sandwich' enzyme-linked immunosorbent assay (ELISA) technique. ELISA reagents were purchased as Opt. EIA Cytokine ELISA sets from Pharmingen (San Diego, CA, USA) and used according to the manufacturer's protocol as follows: 96-well flat bottom plates (Nunc, Maxisorb, Denmark) were coated with anti-cytokine capture antibody diluted in 0.1 M carbonate buffer (pH 9.5) or 0.2 M NaP buffer (pH 6.5), respectively, and were incubated overnight at 41C. The plates were washed twice with phosphatebuffered saline (PBS)-0.2%, Tween 20 and nonspecific binding was blocked by adding special assay diluent containing animal serum, for 1 h at room temperature. After washing the plates, solutions to be tested were added in duplicates (when possible) to wells in parallel with recombinant cytokine standard serial dilutions and incubated for 2 h at room temperature, after which the plates were washed five times and the respective biotinylated anticytokine detection antibody was added together with avidin-horseradish peroxidase conjugated for 1 h incubation at room temperature. After washing the plates six times, TMB (teytramethylbenzidine plus H 2 O 2 ) was added for 30 min at room temperature and the color reaction was stopped by 2 N H 2 SO 4 . Optical density was read immediately by an ELISA reader (Organon Technika, Durham, NC, USA) at 450 nm. A standard curve was generated to determine the cytokine concentration in each sample.
Assay for chimerism
Characterization of the phenotype of mononuclear blood and spleen cells obtained from the surviving recipients was carried out as follows: cells (10 6 ) were incubated with fluorescein isothiocyanate anti-mouse H-2K b or fluorescein isothiocyanate anti-mouse H-2K d (PharMingen, San Diego, CA, USA) at 41C for 30 min, followed by washing with ice-cold PBS containing 1% sodium azide. Freshly stained cells were analyzed by fluorescence-activated cell sorting (FACStar plus, Becton Dickinson, San Jose, CA, USA).
Experimental design I.p. cell injection was carried out on days 0, 2, 5, 7, 9 and 12 following the transplantation of donor spleen cells in F1 conditioned with TBI 700 cGy. Cells were given i.p. in order to serve only as immunological targets (Figure 1) .
Experimental groups included and repeated in six separated experiments were as follows:
Post-transplant i.p. administration of irradiated recipient splenocytes (ISs) serving as stimulatory cells.
Post-transplant i.p. administration of non-irradiated recipient splenocytes (NISs) in an attempt to mimic residual host lymphocytes with replication ability following NST.
Post-transplant i.p. administration of recipient PE grouping an attempt to maximize stimulation of alloreactive donor lymphocytes.
Recipients reconstituted with B6 spleen cells alone served as controls. Animals were followed for body weight and survival as clinical parameters of GVHD.
In separate experiments, the influence of post-transplant recipient cell infusion (RCI) on GVL was evaluated using recipients inoculated with 10 5 BCL1. Assessment of the curative effects of RCI was evaluated at an early stage by BCL1-specific PCR and the long-term GVL effect was evaluated by adoptive transfer experiments.
Statistical analysis
Significance was determined using the Student's t-test and analysis of variance, with post hoc tests using Dunnett's test; Pp0.05 was considered statistically significant. Studies were at least twice repeated.
Effect of post-transplant RCI on mean survival time Mean survival time was significantly shorter in F1 mice treated with RCI injected with NIS as compared to the mean survival time in the control group 9.670.7 and 14.471.6, respectively (n ¼ 27 and n ¼ 39, respectively, P ¼ 0.01) (Figure 2 ). Mean survival time of animals from the IS group was also significantly reduced as compared to the control group, 11.170.5 and 14.871.6, respectively (n ¼ 34 and n ¼ 39, respectively, P ¼ 0.04). F1 mice treated i.p. with RCI consisting of PE also died faster as a result of GVHD (mean survival time 11.570.5, n ¼ 34) but with borderline significance (P ¼ 0.055).
Comparison of different RCI protocols showed that mortality owing to GVHD was faster in NIS recipients as compared with recipients of both IS (P ¼ 0.04) and PE (P ¼ 0.01).
Effect of RCI on GVHD
Clinical signs of GVHD were observed in F1 recipients inoculated with B6 spleen cells, including hunched back, diarrhea and weight loss. Basal mean weight of mice in all groups was 29.272.4 g without any significant differences between the groups. Body weight in all F1 mice receiving B6 allografts declined, and significantly decreased further after RCI, using NIS, IS, PE and also in control groups without significant differences between the groups (although the number of the survivors was reduced by time more rapidly in the groups receiving RCI).
Effect on RCI on engraftment and degree of chimerism Following non-myeloablative conditioning, the average percentage of donor chimerism in the control group reconstituted with B6 spleen cells alone was 53.3711.0% (average7s.e.m., n ¼ 7). Following i.p. injection of either IS or NIS, chimerism increased to 86.872.3 and 86.772.8% (IS recipients, n ¼ 8; NIS recipients, n ¼ 8, with P ¼ 0.002 and P ¼ 0.004, respectively, Figure 3 ). Chimerism in recipients of PE was 56.773.9% (nonsignificant as compared to the control group).
Effect of RCI on GVL effects PCR study. Owing to shorter mean survival time in RCI groups because of enhanced GVHD, the GVL effects induced by B6 spleen cells were evaluated in primary recipients only by testing for residual BCL1 by PCR. PCR for detection of minimal residual BCL1 in splenocytes of recipients of different experimental groups demonstrated no signs of minimal residual disease in neither RCI-treated groups (either NIS, IS or PE) nor in mice reconstituted with spleen cells alone serving as untreated controls. In sharp contrast, all leukemia control animals featured positive Days −1 0 1 2 3 4 5 6 7 8 9 10 1 1 12 13 IV SCT TBI IP RCI using recipient spleen cells or peritoneal exudates Figure 1 Experimental design, all animals received TBI on day À1 followed by SCT on day 0. I.p. RCI was carried out on days 0, 2, 5, 7, 9 and 12 following SCT. RCI source was with ISs serving as stimulatory cells, NISs in an attempt to mimic residual host lymphocytes with replication ability following NST and recipient in an attempt to maximize stimulation of alloreactive donor lymphocytes. Adoptive transfer experiments. In order to compare the intensity of the GVL effects in vivo, an adoptive transfer system was used. After adoptive transfer of 10 5 BCL1, none of the F1 recipients of B6 spleen cells treated with RCI, using either NIS, IS or PE developed leukemia (n ¼ 8, n ¼ 4 and n ¼ 8, respectively), whereas all leukemia control recipients inoculated with an identical number of spleen cells developed leukemia (n ¼ 8, Po0.0001). Likewise, none of the BCL1 recipients transplanted with B6 spleen cells without additional RCI developed leukemia (n ¼ 8, Po0.0001) (Figure 4) .
Cytokines production by spleen cells obtained from recipients of i.p. injected F1 cells
Mean g-interferon production, 24 h after removal of spleens, from F 1 treated by IS (n ¼ 3) and NIS (n ¼ 3) was 34 pg/ml (range 0-102) and 0 pg/ml, respectively. There was no TNFa production 24 h after removal of spleens by either IS or NIS cells (0 pg/ml in both, n ¼ 3).
In vivo cytokine levels in recipients of i.p. injected F1 cells The level of interleukin (IL)-10 was significantly higher (P ¼ 0.003) in the control group (663.3747.3 pg/l (n ¼ 3)) as compared to the recipients treated with IS, NIS and PE (237.57108.8 (n ¼ 6), 213.67264.6 (n ¼ 7) and 180.97105.0 pg/l (n ¼ 8), respectively). No significant difference was seen in the level of g-interferon or TNFa between groups (data not shown).
Discussion
Allogeneic bone marrow or blood SCT represents an important therapeutic tool for the treatment of a long list of otherwise incurable malignant and non-malignant diseases. Until recently, autologous and allogeneic bone marrow or mobilized blood SCT were used primarily to replace malignant, genetically abnormal, or otherwise deficient immunohematopoietic compartments, and therefore highly toxic myeloablative regimens were considered mandatory for eradication of all undesirable host-derived hematopoietic elements. 15 However, animal experiments in the 1960s 16, 17 and clinical observations in the 1970s confirmed that immune-mediated GVL effects play most important role in the course of SCT. 18 Furthermore, since early 1987, we have documented that alloreactive donor lymphocytes infused post-grafting in tolerant hosts, with no additional post-transplant chemotherapy, can eliminate leukemia cells even in patients fully resistant to maximally tolerated doses of chemoradiotherapy. [19] [20] [21] However, the major obstacle in SCT following both myeloablative and non-myeloablative conditioning was and still remains acute and chronic GVHD, still accounting for significant morbidity and mortality. Effector cells of GVHD are exclusively donor T-lymphocytes that react against antigen presentation of host origin, thus causing a wide variety of injuries primarily affecting organs enriched with dendritic cells and to a lesser extent other class II positive antigen-presenting cell (APC), products of the reticuloendothelial system, such as the skin enriched with Langerhans cells, the liver abundant with Kuppfer cells and the gut. When the conditioning, and subsequent infections that are caused by neutropenia, cause extensive dose-related tissue damage, inflammatory cytokines are released, including (IL)-2, TNFa, granulocytemacrophage colony-stimulating factor and g-interferon.
The resulting inflammatory reaction upregulates major histocompatibility complex (MHC) expression, which amplifies the immunogenicity of host cells, and a selfpropagating destructive process is initiated. 22 In the absence of effective treatment for established severe GVHD, the only reliable mode of avoiding severe GVHD is still prevention. This can be achieved by T-cell depletion pre-transplantation or, to a lesser extent, by using various immunosuppressive agents post-transplantation. Another theoretical approach for the prevention of GVHD involves the early administration of autologus CD8-positive cells, probably acting like veto cells. 23 Donor stem cells depleted of T cells have also been shown to act as veto cells of host-versus-graft alloreactivity, 24 thus also suggesting that similarly, host stem cells may also veto graftversus-host alloreactivity, which could explain the mechanism of bilateral unresponsiveness of host-versus-graft and graft-versus-host reactivity in mixed chimeras. 25 As host cells (both stem cells and CD8 þ T cells) may be responsible in part for reduced incidence of GVHD when mixed chimerism is induced post-transplantation on the one hand, and considering the crucial role of host APC, products of host stem cells, on GVHD, [8] [9] [10] [11] it seemed important to investigate the outcome following post-transplant administration of host cells to recipients with an induced process of GVHD following non-myeloablative in comparison with myeloablative conditioning. The results of the experiments represented herewith indicated that both irradiated (serving as stimulatory cells) and non-irradiated host spleen cells (mimicking residual host lymphocytes with replication ability) increased the incidence and severity of GVHD induced by alloreactive lymphocytes administered following the conditioning. However, administration of NIS resulted in a much more accelerated onset and increased severity of GVHD, which also increased the proportion of donor chimerism. Administration of PE cells in order to maximize stimulation of alloreactive donor lymphocytes by additional host origin APCs moderately aggravated GVHD with borderline significance. GVHD and engraftment stimulation was not induced by cytokine production by infused cells, but rather by allogeneic stimulation against the injected cells.
Our results contradict in part to the results of Bittencourt et al., 26 which showed that intravenous injection of apoptotic leukocytes (using irradiation) enhances bone marrow engraftment without increasing GVHD. The veto effect induced by host lymphocytes that may explain the decreased incidence of GVHD in mixed chimeras is mediated by CD8-positive T cells, 23 whereas it seems reasonable that increased incidence of GVHD by administration of host lymphocytes following myeloablative conditioning is mediated by host APC. It seems that there exists a delicate balance, which is difficult to predict between factors that suppress and factors that enhance GVHD when alloreactive donor lymphocytes interact with host alloantigens. In comparison with non-irradiated spleen cells, irradiated cells are likely to migrate to different locations and survive for a shorter period of time in the host, and this may explain their lower capacity to activate donor T cells and enhance GVHD as well as facilitate induction of chimerism.
Interestingly, as shown in Figure 4 , RCI did not impair the GVL effects mediated by alloreactive donor lymphocytes. As the GVL effects induced with donor spleen cells were already curative against a BCL1 challenge of 10 5 cells, it was impossible to determine whether RCI amplified the GVL effects induced spontaneously by donor T cells, as described previously. 27 Additional experiments are underway to explore this important question, using lower number of donor T cells for transplantation on the one hand, and using higher number of BCL1 for more aggressive tumor challenge, on the other, in order to document what seems to be logical, as enhanced GVHD is likely to enhance GVL effects in parallel. It would have been of interest to examine whether injection of host NIS or IS leads to an increased expansion and enhanced activation of cytotoxicity of donor T cells. Unfortunately, considering the fact that in a given immunological reaction, the number of antigen-or alloantigen-specific T cells is low, such an experimental system may be difficult to establish.
As noted, PE cells were less potent than NIS and IS with regard to induction of GVHD and in facilitating engraftment of donor cells, as documented by donor cell chimerism. However, such an effect may reflect a balance between the capacity of PE cells (most of them macrophages, data not shown) to present host alloantigens, which could enhance GVHD and engraftment on the one hand, versus the immunosuppressive effect of such cells, either cell-mediated or mediated by cytokines that can be secreted by PE.
In conclusion, although the exact role of different host cell subsets as well as their route of administration remains to be elucidated, our results suggest that host cells remaining in the recipient following a non-myeloblative conditioning may serve as antigen presentation, thus enhancing antihost reactivity and GVHD. This may explain, in part, the higher than expected GVHD after NST and the rapid displacement of host cells and conversion to 100% donor chimerism. Obviously, in addition to the theoretical importance of understanding the mechanisms involved, the positive evidence that RCI post-transplantation, including irradiated host cells, can amplify GVHD could justify the use of such cells, cryopreserved and irradiated before or after the transplantation, for amplification of GVL effects in patients with no signs of GVHD, who are at higher risk of relapse.
